I-ACT for Children selects Advarra to accelerate paediatric clinical trials network

22nd May 2019 (Last Updated May 22nd, 2019 15:02)

The Institute for Advanced Clinical Trials for Children (I-ACT for Children) has selected Advarra to provide central institutional review board (IRB) services to accelerate its paediatric clinical trials network.

The Institute for Advanced Clinical Trials for Children (I-ACT for Children) has selected Advarra to provide central institutional review board (IRB) services to accelerate its paediatric clinical trials network.

The collaboration will focus on the timely completion of global paediatric studies and speed up the site start up. Advarra chief executive officer Pat Donnelly said: “Advarra is proud to have been chosen by I-ACT for Children as its central IRB provider. Together, we will help catalyse improvements in paediatric health by contributing to the timely completion of much needed paediatric studies.”

I-ACT for Children chief executive officer Laura Gordon said: “Providing central IRB services as part of our site network is an important part of accelerating and enhancing the efficiency of paediatric clinical trials, which is central to our mission.

“Every child with a medical need deserves the best chance possible; selecting Advarra as the central IRB for our site network underscores our dedication to driving innovation, quality, and urgency as we work to advance medical therapies specifically for children.”

Based in the US, I-ACT for Children is a non-profit organisation focusing  on the advancement of paediatric clinical trials.

The company aims to cater to unmet medical needs by supporting the development of novel medicines and devices for children.

It also seeks to optimise biomedical innovation using child-centered clinical trial networks by collaborating with like-minded institutions and other stakeholders.

Currently, the I-ACT for Children site network operates nearly 44 US paediatric research sites.

Advarra, also based in the US, provides independent institutional review board (IRB), institutional biosafety committee (IBC), and global research compliance services to pharmaceutical companies, universities, individual researchers, academic medical centres, and hospital systems.